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tumor necrosis factor-related apoptosis-inducing ligand; TREM2: triggering receptor expressed 
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Abstract 
Currently there is no cure for Alzheimer’s disease (AD); clinical trials are underway to 
reduce amyloid generation and deposition, a neuropathological hallmark in brains of AD 
patients. While genetic factors and neuroinflammation contribute significantly to AD 
pathogenesis, whether increased cholesterol level is a causative factor or a result of AD is 
equivocal. Prenylation of proteins regulating neuronal functions requires mevalonate-derived 
farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). The observation that 
the levels of FPP and GGPP, but not that of cholesterol, are elevated in AD patients is consistent 
with the finding that statins, competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG CoA) reductase, reduce FPP and GGPP levels and amyloid β protein production in 
preclinical studies. Retrospective studies show inverse correlations between incidence of AD and 
the intake and serum levels of the HMG CoA reductase-suppressive tocotrienols; tocopherols 
show mixed results. Tocotrienols, but not tocopherols, block the processing and nuclear 
localization of sterol regulatory element binding protein-2, the transcriptional factor for HMG 
CoA reductase and FPP synthase, and enhance the degradation of HMG CoA reductase. 
Consequently, tocotrienols deplete the pool of FPP and GGPP and potentially blunt prenylation-
dependent AD pathogenesis. The anti-inflammatory activity of tocotrienols further contributes to 
their protection against AD. The mevalonate- and inflammation- suppressive activities of 
tocotrienols may represent those of an estimated 23,000 mevalonate-derived plant secondary 
metabolites called isoprenoids, many of which are neuroprotective. Tocotrienol-containing plant 
foods and tocotrienol derivatives and formulations with enhanced bioavailability may offer a 
novel approach in AD prevention and treatment.   
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1. Introduction 
The socioeconomic burden of Alzheimer’s disease (AD) coupled with lack of a clear 
understanding of its molecular mechanism and effective treatments call for more in-depth 
investigations of this debilitating disease with novel approaches. Here we first summarize the 
risk factors including genetic variation, heredity, age and neuroinflammation, and follow up with 
the fundamentals of AD pathogenesis. The ambiguous link between AD and cholesterol levels in 
plasma, serum and brain tissues stands in contrast with a notable observation that intermediates 
of the mevalonate pathway by which cholesterol is synthesized are elevated in AD patients; these 
intermediates support prenylation of proteins regulating neuronal function. The preclinical 
studies of statins that inhibit the biosynthesis of these mevalonate-derived intermediates, albeit 
with equivocal clinical outcomes, lend support to the preventive and therapeutic potentials of 
mevalonate-suppressive tocotrienols, vitamin E molecules with structures and biological 
activities distinct from those of the more commonly studied tocopherols. Emerging literature also 
reveals a variety of neuroprotective activity of tocotrienols. We delineate potential mechanisms 
of tocotrienols based on their impact on the mevalonate pathway that, when coupled with their 
anti-inflammatory activity, renders them – and potentially the broad class of dietary 
phytonutrients they represent – promising candidates in protection against AD. 
 
2. Risk Factors for AD 
 Risk factors associated with AD have been identified through their functional and 
physical interaction with neuropathological proteins of AD, amyloid β protein (Aβ) and Tau. 
Age and greater inflammation are well-established risk factors, and multiple genes have been 
found to facilitate the disease onset and progression.  
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a. Genetic variation  
 Genetic and neuropathologic evidence suggests that AD is caused in part by the 
overproduction and lack of clearance of Aβ [1, 2], accompanied by enhanced neuroinflammation 
[3]. Detrimental mutations in genes encoding presenilin 1 and 2 (PS1 and PS2) and amyloid 
precursor protein (APP) alter APP processing mediated by β-secretase (BACE1) and γ-secretase 
(a.k.a. PS1/2) [4-6], leading to an increased ratio of Aβ42/Aβ40 and to early onset familial AD. 
A beneficial mutation in APP reduces Aβ production and protects against the onset of sporadic 
AD [7]. 
  Genetic analysis of risk factors reveals that one or two aberrant copies of the 
apolipoprotein E (ApoE) ε4 alleles are a major risk factor for late-onset sporadic AD. The risk 
factor gene ApoE has three major isoforms, ApoEε2, ε3, and ε4. ApoEε3 is found in the majority 
of the healthy population; ApoEε2 allele is found to be protective from incidence of AD, and 
ApoEε4 allele is the strongest known risk factor for AD. The major receptor for all forms of 
ApoE is the low-density lipoprotein receptor (LDLR) that regulates amyloid plaque deposition, 
and overexpression of the LDLR enhances blood-brain barrier-mediated ApoEε2, ε3, and ε4 
clearance, thus leading to reduced Aβ accumulation [8]. Brains of sporadic AD patients carrying 
the ApoEε4 allele were found to have an increased density of Aβ deposits and a limited 
capability to clear Aβ [3]. The AddNeuroMed Project, a multicenter European longitudinal 
study, examined the biomarkers for AD; assessment of 168 AD patients, 166 subjects with mild 
cognitive impairment (MCI), and 187 cognitively normal (CN) people found that the percentages 
of subjects carrying any ApoEε4 allele were 52%, 41% and 29%, respectively, in these three 
groups, suggesting a potential correlation between neurodegeneration and ApoEε4 [9].  
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b. Heredity 
 The majority of AD cases are sporadic in nature, and a small percentage of AD patients 
are familial cases. Currently, only three genes, PS1, PS2 and APP, are known to cause AD. 
Autosomal dominant mutations in PS1, PS2 and APP lead to early onset, familial AD, and 
mutant PS1 accounts for the majority of these inherited cases. Interestingly, PS1/PS2 are the 
enzyme called γ-secretase that cleaves the precursor to generate Aβ, and APP is the precursor of 
Aβ [4-6]. Therefore, mutations in either enzyme or precursor of Aβ initiate onset of disease in all 
familial cases.  
 
c. Age and inflammation 
 Epidemiological studies reveal that aging is the single most significant risk factor 
contributing to AD. Among elderly at 65 years old and above, 5% of them have sporadic or 
familial AD. This number dramatically increases to 50% in elderly over 85 years old. Many 
factors associated with aging directly or indirectly contribute to the pathogenesis of AD. As 
imbalanced Aβ homeostasis is an upstream event of neuroinflammation and neurodegeneration, 
enhanced microgliosis and astrocytosis are directly associated with neuronal loss. Previous 
studies have shown that some microglia cells originate from the bone marrow. These cells can 
migrate towards Aβ plaques, mainly because of attraction by Aβ42. These microglia cells are 
able to eliminate Aβ by phagocytosis, which provides a novel therapeutic opportunity for bone 
marrow stem cells to remove Aβ deposit in brains of AD patients [10]. Genetic mutations found 
in several genes lead to changes to immune molecules and reduce Aβ uptake. Mutations in the 
microglial receptor TREM2 (triggering receptor expressed on myeloid cells 2) triple a person’s 
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risk for AD [11, 12]. CD33 is another gene linked to AD and functions to suppress Aβ uptake 
and clearance. AD risk variants reduce expression of CD33 [13, 14]. Systemic analysis of 
hundreds of AD brains reveals changes in networks related to immunologic molecules and 
microglial cells, including microglial protein TYROBP that binds TREM2 and may regulate 
CD33 [15]. 
 Physiological alteration provides manifestation of risk factors associated with AD 
pathogenesis. Many responses characteristic of AD are in part triggered by Aβ. Interleukin-1β is 
implicated in AD and inflammatory disorders. When microglia cells engulf extracellular 
aggregates such as Aβ, they trigger inflammasomes (such as NOD-like receptor family pyrin 
domain-containing 3 (NLRP3)), activate caspases and promote IL-1β release [16]. This pathway 
was validated in AD transgenic mice where NLRP3 was shown to contribute to AD-like 
pathology in mouse brains [17]. Recent studies have shown that Aβ can bind to scavenger 
receptors expressed on microglia such as CD36 – a central regulator of immune responses that 
drives inflammatory diseases [18] – enter microglia and activate inflammation. Another 
scavenger receptor Scara1 function similarly to CD36 and clears extracellular Aβ [19].  
 
3. AD Pathology 
a. Plaques and tangles  
 Neuritic plaques and neurofibrillary tangles (NFT) are two characteristic hallmarks in 
brains of AD patients. Neuritic plaques are composed of heterogeneous Aβ peptides. 
Biochemical/immunohistochemical findings have revealed neurotoxic properties of different Aβ 
isoforms in brain. Compared to shorter Aβ peptides like Aβ40 and Aβ38, the 42-residue Aβ42 
enhances aggregation propensity [20], leading to accelerated formation of small (low-n) Aβ 
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oligomers (oAβ) [21]. It has been documented that the oligomeric form of Aβ seems to be the 
most toxic species of Aβ as well as the precursor to the fibrillary Aβ found in senile plaques [1, 
21-24].  
 The second hallmark of AD is NFT. Hyperphosphorylated Tau is the main component of 
NFT. Phosphorylated Tau appears early in neurons from subjects suffering MCI and accumulates 
in neurofibrillary neurons as AD progresses. They localize to the dystrophic neurites, a change 
correlating with synaptic and cognitive deficits. Phosphorylated Tau gradually loses normal 
function to promote microtubule assembly and becomes highly stable and prone to aggregation. 
 
b. Role of cholesterol and mevalonate pathway in causing plaques and tangles 
 Preclinical studies suggest the cholesterol-AD connection, though evidence for whether 
elevated cholesterol level is a causative factor or a casualty of AD is equivocal. A 
hypercholesterolemic diet increased the Aβ load in a transgenic mouse model [25]. Dietary 
cholesterol induced a two-fold increase in Aβ concentration in rabbit hippocampal cortices [26], 
and accumulation of Aβ can be reversed by removing cholesterol from diet [27]. Early studies 
using partially purified γ-secretase complex were carried out to understand the effect of 
cholesterol on its activity. When different levels of cholesterol were presented in membrane 
vesicles composed of a known content of phospholipids such as phosphotidylethanolamine and 
phosphotidylcholine, efficacy of γ-secretase cleavage of its substrate to generate Aβ40 and Aβ42 
was either dramatically increased or decreased depending on the composition of phospholipids. 
However, there is no direct relationship between the amount of cholesterol and the level of 
phospholipids such as phosphotidylethanolamine and phosphotidylcholine. Statins, competitive 
inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl 
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coenzyme A (HMG CoA) reductase, directly decrease cholesterol levels and reduce processing 
of APP and generation of Aβ in cell-based studies. When farnesyl pyrophosphate (FPP), 
geranylgeranyl pyrophosphate (GGPP), cholesterol and Aβ40 were quantified in cells treated 
with different inhibitors, reduction of Aβ40 was found in the presence of lovastatin and an 
oxidosqualene cyclase inhibitor that block cholesterol synthesis [28]. In transgenic mice 
modeling AD, simvastatin improves hippocampus-dependent spatial memory and rescue 
memory deficits. Furthermore, simvastatin potentiates the N-methyl-D-aspartate receptor-
mediated synaptic transmission [29]. Additional evidence suggested that modulation of neuronal 
activity by APP is mediated by decrease in cholesterol biosynthesis and hydroxylation [30].  
 Retrospective and prospective studies in humans do not always produce consistent 
outcomes [31]. A number of retrospective studies found a lower prevalence of AD in subjects 
taking statins compared to those not taking statins. A nested case-control study derived from the 
UK-based General Practice Research Database examined 284 cases with dementia and 1080 
controls; individuals of 50 years and older who were prescribed statins had a significantly lower 
adjusted relative risk of dementia including AD with an odds ratio (OR) of 0.29 and 95% 
confidence interval (CI) of 0.13-0.63 (P = 0.002) [32]. A cross-sectional analysis showed that 
patients taking statins had a 60-73% (P < 0.001) lower AD prevalence than the total patient 
population and those taking other medications for hypertension or cardiovascular diseases [33]. 
An observational study followed 342 AD patients (108 normolipidemic, 105 untreated 
dyslipidemic, and 129 dyslipidemic treated with lipid-lowering agents (LLAs) including 47% 
with statins) with the mean age of 73.5 years for 34.8 months; patients treated with LLAs had a 
slower decline on the mini-mental state examination score (P = 0.0102) than patients with 
untreated dyslipidemia or normolipidemia. Treatment with LLAs was positively associated with 
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the probability of lower cognitive decline (OR = 0.45, P = 0.002) [34]. However, the hypothesis 
that cholesterol is involved in the development of AD is plagued by inconsistent plasma, serum 
or brain cholesterol levels in AD patients, the lack of efficacy of statins in prospective studies, 
and potential non-Aβ protein targets affected by cholesterol modulation [31]. 
 
c. Potential for prevention and treatment of AD by blocking the mevalonate pathway 
Cholesterol is synthesized via the mevalonate pathway consisting of multiple enzymes 
that include, among others, HMG CoA reductase and FPP synthase (Figure 1) [35]. In addition to 
the bulk end product cholesterol, the mevalonate pathway also produces many non-sterol 
intermediates such as FPP. FPP can also be directed for the synthesis of GGPP by GGPP 
synthase. FPP and GGPP serve as the lipid substrates for protein prenylation, an essential step in 
the membrane anchoring and biological activities of a number of membrane proteins including 
the nuclear lamins and small G proteins such as Ras, Rho, Rac and Rab [36]. Prenylation of 
proteins facilitates protein-protein interaction and the prenylation status of small G proteins 
determines their membrane association and subcellular locations [37], which regulates many 
cellular functions including synaptic plasticity.  
Previous studies have demonstrated that FPP and GGPP levels in AD patients are 
elevated by 36% and 56%, respectively, as compared to age-matched controls without a 
significant change in cholesterol levels or HMG CoA reductase expression [31, 38]. These 
findings suggest that mevalonate-derived non-sterol factors might play a role in AD 
pathogenesis. The observation that patients treated with LLAs had lower cognitive decline than 
those with normolipidemia also supports a potential role of non-sterol factors [34]. 
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Elevation of FPP and GGPP was caused by an increased expression of FPP and GGPP synthases, 
which provide additional FPP and GGPP for protein prenylation of small G proteins. Statins 
reduce levels of FPP and GGPP as a consequence of inhibition of HMG CoA reductase. GGPP 
stimulates γ-secretase and increases the production of Aβ [39], an effect reversed by statin-
induced blockage of protein prenylation [40]. Conversely, in cell culture lovastatin induced 
neurite outgrowth, an effect reversed by geranylgeraniol [41]; geranylgeraniol might be 
phosphorylated and converted to GGPP to support prenylation and suppress neurite outgrowth. 
Increased prenylation of small GTPase Rho1, the fly orthologue of vertebrate RhoA, induced 
neurodegeneration in Drosophila [42]. In AD transgenic mice, simvastatin-mediated depletion of 
FPP and inhibition of farnesylation promote enhancement of hippocampal long-term potentiation 
[43].  
 The potential role of prenylation in AD pathophysiology has led to studies exploring 
whether farnesyl transferase inhibitors (FTIs), geranylgeranyl transferase inhibitors, and 
bisphosphonates (inhibitors of FPP synthase) may have impact on AD [44]. In a transgenic 
mouse model overexpressing mutant APP and PS1 genes, deleting one copy of 
farnesyltransferase reduced Aβ deposition and neuroinflammation; behavioral tests reveal a 
rescue of spatial learning and memory function [45].  
 
4. Tocotrienol, Mevalonate Pathway, and AD 
Literature suggests that plant-based foods have neuroprotection effects. A prospective 
cohort study of 3,718 human subjects aged 65 years and older based on food frequency 
questionnaire assessed cognitive functions at baseline and 3-year and 6-year follow-ups. The 
rates of cognitive decline among persons in the fourth and fifth quintiles of vegetable intake were 
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slower by 0.019 (P = 0.01) and 0.018 (P = 0.02) standardized units per year compared with that 
among persons in the lowest quintile; the overall mean change per year was a decline of 0.04 
standardized units [46]. Strawberry, spinach and blueberry extracts protect against age-related 
neuronal decline. Extracts of these fruits and vegetable fed to 19-month-old Fischer 344 rats for 
8 weeks reversed age-related deficits in several neuronal and behavioral parameters. Blueberry 
particularly improves motor function that relies on balance and coordination [47]. These fruits 
and vegetables contain a large number of isoprenoids [48], secondary metabolites of the plant 
mevalonate pathway [49]. The estimated 23,000 [50] isoprenoids include pure and mixed 
isoprenoids; the former consist of multiples of the five-carbon mevalonate-derived isoprene unit 
and include mono-, sesqui-, di-, tri- and poly- terpenoids depending on the number of the 
isoprene units in the isoprenoid structure, and the latter are partially built with isoprenes in their 
structures. A number of isoprenoids, including the monoterpenes 1,8-cineole and geraniol, the 
sesquiterpene valerenic acid, the diterpene ginkgolide A, and the triterpene ginsenoside Rg1, 
have been found to possess neurological effects via actions such as inhibition of cholinesterase 
and modulation of γ-aminobutyric acid [51]. In cultured rat cortical neurons, the tetraterpene 
lycopene protects against Aβ-induced neurotoxicity [52].  
 The isoprenoids bear striking resemblance with the statins in suppressing HMG CoA 
reductase activity, albeit via mechanisms distinct from the competitive inhibition of statins. In 
eukaryotic cells HMG CoA reductase is subject to a multivalent regulation at the transcriptional 
and posttranscriptional levels. Cholesterol and its oxygenated products elicit a negative feedback 
inhibition on the transcription of the enzymes in the pathway, including HMG CoA reductase 
and FPP synthase, via the transcriptional factor sterol regulatory element binding protein 2 
(SREBP-2); membrane cholesterol prevents the cleavage and nuclear localization of SREBP-2. 
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A non-sterol isoprenoid, currently identified as the diterpene geranylgeraniol or a 
geranylgeraniol-derived product, at the presence of sterols, enhances a proteasome-mediated 
degradation HMG CoA reductase [53]. Several monoterpenes including d-limonene, perillyl 
alcohol and geraniol and the sesquiterpenes trans, trans-farnesol [49, 54, 55] and β-ionone [56] – 
in addition to the diterpene geranylgeraniol [57] – have been shown to suppress HMG CoA 
reductase activity (Figure 1). 
The most potent reductase suppressors identified to date among the isoprenoids are the 
tocotrienols, vitamin E molecules with a farnesyl side chain. The vitamin E family is comprised 
of α-, β-, γ- and δ- tocopherols and their tocotrienol counterparts, a total of eight molecules 
(Figure 2). Tocotrienols block the processing and maturation of SREBP-2 and enhances the 
degradation of HMG CoA reductase [58, 59]. The tocotrienols differ from tocopherols, the 
widely studied and publicized vitamin E family members, in structures, biological activities and 
health impacts. The parallel effect of statins and tocotrienols on HMG CoA reductase activity is 
mirrored in their shared biological activities including hypocholesterolemic [60], anti-cancer 
[61], anti-inflammatory [62] and bone-protective effects [63]. In contrast, the tocopherols with a 
saturated phytyl tail do not impact the degradation of HMG CoA reductase [58] or affect the 
maturation of SREBP-2 at physiological concentrations [64]. In many studies tocopherols lack 
the biological activities of tocotrienols [65-68] or even attenuate the tocotrienol effects [69, 70]. 
Lower incidences of both AD and MCI were found in populations carrying higher levels 
of tocotrienol and tocopherol. In an 8-year follow-up to the Cardiovascular Risk Factors, Aging, 
and Dementia study, the subjects in the middle tertile of the γ-tocopherol/cholesterol ratio had a 
lower risk of cognitive impairment – the multi-adjusted OR with 95% CI was 0.27 (0.10-0.78) – 
than those in the lowest tertile. The highest tertile of the serum total tocopherol was not 
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associated with a lower incidence of cognitive impairment (OR of 1.10 with 95% CI of 0.44-
2.70). As a comparison, the highest tertile of the serum total tocotrienol had an OR of 0.84 with 
95% CI of 0.35-2.04. Furthermore, the highest tertile of the serum γ-tocotrienol, a tocotrienol 
with a potent HMG CoA reductase-suppressive activity [58, 59], had an OR of 0.50 with 95% CI 
of 0.20-1.26. The highest tertile of the serum α-tocotrienol – with its much weaker HMG CoA 
reductase-suppressive activity [58, 59] – had an OR of 1.18 with 95% CI of 0.49-2.86 [71]. In 
the aforementioned AddNeuroMed Project, the mean plasma levels of individual vitamin E 
molecules, total tocopherols, total tocotrienols, and total vitamin E in AD subjects were lower 
thank those in the CN subjects; MCI and AD patients were 92% (OR of 0.08 with 95% CI of 
0.02-0.26) and 94% (OR of 0.06 with 95% CI of 0.02-0.21) less likely to be in the highest tertile 
of total plasma tocotrienols than the lowest tertile [9]. In MRI scans, levels of vitamin E provide 
acceptable sensitivity and specificity to differentiate AD and MCI from control subjects, and 
predict conversion of MCI subjects to clinical AD after 1 year [72]. Additional studies suggest 
that tocotrienols rather than tocopherols may provide protection. The incidence of AD was 
inversely associated with combination of different forms of vitamin E rather than a single 
isoform of α-tocopherol in a 6-year follow-up study of 232 subjects aged 80+ years; multi-
adjusted hazard ratios for developing AD and 95% CI for total tocopherols, total tocotrienols, 
and total vitamin E were 0.55 (0.32-0.94), 0.46 (0.23-0.92), and 0.55 (0.32-0.94), respectively, 
when comparing persons in the highest and lowest tertiles [73]. Comparison of human subjects 
taking different isoforms of vitamin E indicates that mixtures of tocopherols and tocotrienols 
rather than α-tocopherol alone exhibit protection against AD. A 4-year follow-up in the Chicago 
Health and Aging Project (1993-2003) assessed 1041 persons with 162 AD cases; the adjusted 
relative risks of incident AD per 5 mg/d increase in intake of α-tocopherol and α-tocopherol 
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equivalents with 95% CI were 0.66 (0.43-1.03) and 0.56 (0.32-0.98), respectively [74]. In studies 
showing the inverse correlation between tocotrienol and cognitive decline, the age of subjects 
ranged from early [71] and mid 70s [9, 72, 74] to mid 80s [73]. There is no apparent association 
between the impact of tocotrienol and the age of subjects based on reported ORs in a limited 
number of studies, though the single study with the oldest subjects seemed to show the lowest 
OR value with tocotrienol [73]. In a separate study with a younger population in which 121 
subjects aged ≥ 35 years with cardiovascular risk factors and white matter lesions (WMLs) were 
given 200 mg mixed tocotrienol twice a day, the mean WML volume was found to be 
significantly lower in the group supplemented with tocotrienol as compared to the placebo group 
(P = 0.019) at the end of 2-year study [75]. Studies of supplementing AD patients with vitamin E 
containing tocopherols as the primary components result in variable outcomes and no clear 
beneficial effect for AD patients [76, 77].  
Epidemiological evidence for the inverse correlation between tocotrienol and AD 
incidence is consistent with preclinical studies showing neuroprotective activity of tocotrienols. 
α-Tocotrienol was more effective than α-tocopherol in preventing cognitive deficits in rats 
induced by intracerebroventricular streptozotocin insult. Behavioral tests using Morris water 
maze clearly reveal a rescue of memory dysfunction by tocotrienol, which effectively reduced 
malondialdehyde and nitrite, and attenuated the decreases in glutathione and catalase [78, 79]. 
Supplementation with tocotrienol-rich-fractions reduced anxiety, improved spatial learning and 
memory, reduced DNA damage and level of malondialdehyde, and increased antioxidant activity 
in aged rats [80]. Tocotrienols attenuated neurite degeneration induced by 2,2’-azobis (2-
methylpropionaide) dihydrochloride [81] and may also suppress elevated oxidative stress and 
mitochondrial injury. Additionally, tocotrienols maintain cell survival against neuro injury 
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caused by glutamate, the main excitatory neurotransmitter that becomes excitotoxic under 
disease conditions [82, 83].  
It is unknown whether the correlation between tocotrienol intake and AD risk is 
attributable to tocotrienol-mediated HMG CoA reductase suppression and consequent decrease 
in FPP and GGPP, though the latter would be consistent with tocotrienol-mediated blockage of 
SREBP-2 maturation. Lending support to the reductase hypothesis is the finding that, in addition 
to statins and aforementioned isoprenoids, the reductase-suppressive resveratrol [84], a 
polyphenol found in grape skin and red wine – among other food sources – triggers autophagy 
and lysosomal degradation of Aβ in APP-HEK293 cells and reduces cerebral Aβ levels and 
deposition in the cortices in mice [85]. The aforementioned statin-mediated reduction of FPP and 
GGPP observed in preclinical studies has not manifested in human studies, a plausible cause for 
equivocality of statins in human trials.  
 
5. Tocotrienols and Inflammation 
The anti-inflammatory activity of tocotrienols may have contributed to their potential 
protection against AD. In human breast cancer cells [86, 87], colon carcinoma cells [88], 
malignant melanoma cells [89], pancreatic cancer cells [90], gastric cancer cells [91], metastatic 
oral cancer cells [92], adipocytes [93, 94], and macrophages [95-98], tocotrienols inhibit the 
DNA-binding activity of nuclear factor kappa B (NFκB), a major mediator in chronic 
inflammation, and suppress tumor necrosis factor α- and lipopolysaccharide (LPS)-induced 
NFκB expression. Moreover, the in vitro NFκB-suppressive activity of tocotrienols manifested in 
gastric cancer [91] and pancreatic cancer [99] in nude mice and in the cerebral cortices and 
hippocampi of ethanol-fed rats [100]. Recent reviews [101-103] have summarized the anti-
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inflammatory activity of tocotrienols. 
The finding that tocotrienol-mediated ablation of NFκB activity was reversed by 
supplemental mevalonate [104], the product of HMG CoA reductase, suggests that reductase 
suppression mediates the anti-inflammatory activity of tocotrienols and may unify that of diverse 
isoprenoids. The monoterpenes limonene and trihydroxy ketone E-4-(1,2,4-trihydroxy-2,6,6,-
trimethylcyclohexyl)-but-3-en-2-one inhibited NFκB activation in human HL60 clone 15 
leukemia cells [105] and PC-3 prostate cancer cells [106], respectively. α-Pinene and geraniol, 
two monoterpenes found in Salvia lavandulaefolia (Spanish sage) essential oil, inhibited the 
production of thromboxane B2 and leukotriene B4, respectively, in rat leucocytes [107]. The 
monoterpenes hookerinoids A and B isolated from the herb Pterocephalus hookeri inhibited 
NFκB expression in a reporter luciferase assay in human embryonic kidney HEK293 cells [108]. 
Perillyl alcohol, an oxidative product of limonene, suppressed NFκB in B-lymphoma [109], 
while geraniol suppressed 12-O-tetradecanoyl phorbol-13-acetate (TPA)-induced inflammatory 
responses and up-regulation of NFκB and cyclooxygenase-2 in mice [110, 111]. The 
monoterpenes isopropoxy-carvacrol [112], 4’-geranyloxyferulic acid [113] and (-)-myrtenol 
[114] also showed anti-inflammatory activity in mice. A sesquiterpene β-ionone inhibited TNF–
related apoptosis-inducing ligand (TRAIL)-induced NFκB activation in human HepB3 and 
HepG2 hepatocellular carcinoma cells [115], and farnesol attenuated the 1,2-dimethylhydrazine-
induced infiltration of the inflammatory cells in mucosal and submucosal layers of the colon of 
Wistar rats [116]. Over 100 sesquiterpene lactones blocked NFκB activity [117, 118], while 
parthenolide inhibited the inflammasome [118]. Diterpene coronarin D suppressed NFκB 
activation in human KBM-5 chronic myeloid leukemia and A293 embryonic kidney carcinoma 
cells [119]. Another diterpene carnosol reduced LPS-stimulated nitric oxide production and 
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NFκB in RAW 264.7 cells [120], reduced pro-inflammatory leukotrienes in human 
polymorphonuclear leukocytes [121], and inhibited cyclooxygenase-2 in 184B5/HER human 
mammary epithelial cells [122]. Garcinol, a mixed polyisoprenoid, inhibited the activation of 
NFκB in human BxPC-3 and Panc-1 pancreatic cancer cells [123] and squamous cell carcinoma 
of the head and neck [124]. Additionally, a triterpene lupeol suppressed TPA-induced activation 
of NFκB in CD-1 mice [125]. The HMG CoA reductase suppressive tetraterpene lycopene [126-
128] suppresses the production of tumor necrosis factor-a and activation of NFκB, CD14 and 
Toll-like receptor 4 in LPS-activated primary human umbilical vein endothelial cells [129] and 
abrogates Aβ-mediated neuroinflammatory cascade and learning and memory deficits [130] 
while ameliorating fructose-induced neuroinflammation and cognitive impairment [131] in 
experimental models of AD. 
Coincidentally, accumulating evidence supports the anti-inflammatory and NFκB 
suppressive activity of statins [132-135]. Reminiscent of the findings with tocotrienols [104], 
mevalonate attenuated the simvastatin effect on NFκB [136]. Whether mevalonate deprivation 
and anti-inflammation mediate the potential roles of statins and tocotrienols in AD and the 
neuromodulatory activity of isoprenoids warrants further studies. 
 
6. Current Therapeutics and Potential of Tocotrienols as Preventive/Therapeutic Agents 
Since neuropathological hallmarks in the brains of AD patients include Aβ-containing 
neuritic plaques and Tau-containing neurofibrillary tangles, therapeutic efforts have been 
devoted to agents that may effectively reduce the pathology. A number of amyloid-based 
therapeutics have been developed and tested in clinical trials. Although several high-profile 
phase III clinical trials failed in the past several years, recent findings in maintaining cognitive 
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function by Biogen’s immunotherapy provide strong evidence to support the validity of amyloid-
based therapies. 
In clinical trials, the antibody Aducanumab (BIIB37) performs best among many 
immunotherapies, such as AAB-003 by Janssen/Pfizer, ACI-24 by AC Immune, Affitope AD02 
by AFFiRiS AG, BAN2401 by Eisai, LY3002813 by Eli Lilly, MED1814 by AstraZeneca, and 
SAR228810 by Sanofi. Uniquely, Aducanumab recognize amino acid 3-6 of aggregated Aβ but 
not monomeric Aβ. For the clinical trial of Aducanumab, enrolled subjects underwent amyloid 
PET tracer florbetapir to confirm diagnosis of early AD. The results from the phase I study 
revealed that amyloid deposit levels dropped in all treatment groups after 6 months and even 
more after one year, while the control group receiving the placebo showed a slight increase in 
amyloid deposit. These results clearly show the target engagement and demonstrate a reduction 
of amyloid deposit by Aducanumab. Aducanumab is the only agent in clinical trials that 
demonstrates a clinical benefit to cognitive function, such as MMSE and CDR-SB tests. A 
lower-point drop was found in the group receiving the antibody, compared to a greater-point 
drop in the placebo group. The overall positive responses from the phase I trial prompted a direct 
entry of Aducanumab into phase III trials [137]. 
A second class of promising amyloid-based therapies is the β-secretase inhibitors, 
including AZD3293 by AstraZeneca, BI 1181181 by Boehringer Ingelheim, E2609 by Biogen, 
JNJ-54861911 by Janssen, and MK-8931 by Merck (phase III). These compounds are highly 
potent and reduce Aβ in animals and humans; success in any one of these compounds in clinical 
trials would further support the validity of amyloid-based therapies for AD. 
Despite the multiple therapeutics tested in the past decade to reduce the pathological 
burden and to maintain cognitive function, the molecular mechanism of AD pathogenesis is still 
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not completely clear. Toxicities – such as those associated with some recent γ-secretase 
inhibitors – and lack of efficacy preclude a cure for AD to date.  
Extensive in vitro, in vivo and human studies have demonstrated the safety of tocotrienols 
derived from oils of palm, rice bran and annatto seed [138]. Palm- (GRN 000307) and annatto- 
(GRN 000471) derived tocotrienols have obtained FDA-approved Generally Recognized As Safe 
(GRAS) status. At non-toxic levels, tocotrienols and tocotrienol-containing formulations were 
found to possess triglyceride- [139, 140] and cholesterol- [140] lowering, anti-inflammatory 
[140] and neuroprotective [141, 142] effects in humans. The safety profile of tocotrienols, 
coupled with their impacts on the mevalonate pathway and inflammation – mechanisms 
delineated in sections 4 and 5 of this review – renders tocotrienols promising agents for AD 
prevention or therapy. 
 
7. Summary and Future Directions 
The potential of tocotrienols in AD prevention or treatment is likely dependent on their 
impact on the mevalonate pathway, SREBP-2 processing, cholesterol biosynthesis, 
inflammation, and neuroprotection. Strawberry, spinach and blueberry extracts protect against 
age-related neuronal decline with mixed effect on antioxidant status; reactive oxygen species 
(ROS), but not glutathione, were reduced. The differential effects of tocotrienols and tocopherols 
in protection against AD and the finding that FTIs reduce ROS production and increase the 
viability of mouse neuronal cortical cells [143] suggest that antioxidant activity may be 
secondary to prenylation inhibition. 
In conclusion, the potential effects of tocotrienols on the mevalonate pathway 
intermediates FPP and GGPP and inflammation, coupled with the safety profile of tocotrienols - 
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distinctive from those of the experimental drugs - render these vitamin E molecules promising 
candidates for AD prevention and/or treatment. The broad plant-food-based sources for 
tocotrienols, including avocados, bananas, berries, cabbage, cherries, coconut, corn, Kiwi, green 
pea, onions, peaches, pears, plums [144-146], grape [147, 148], peanuts [149], hazelnut [150], 
cashew [151], horse chestnuts, litchi [152, 153], cereals, wheat [154], olive fruit [155], annatto 
[156], and specialty oils from palm, rice bran, barley, and oat [157, 158] suggest that protection 
against AD mediated by tocotrienols and potentially the mevalonate-suppressive isoprenoids 
may be nutritionally relevant. Preclinical and clinical studies need to determine the efficacy and 
mechanism of action of tocotrienol. Once targets for tocotrienols are identified, tocotrienol 
derivatives [159] and novel formulations such as self-emulsifying drug delivery systems [160, 
161], nanoemulsion [162], and nanoparticles [163] with enhanced bioavailability, accurate target 
delivery and engagement, and higher potency could be developed. Combinations of tocotrienols 
with other pharmaceutical and non-pharmaceutical approaches, each with different, but 
preferably complementary, mechanisms of action for greater efficacy and yet less adverse 
effects, may further add to the potential of this class of agents as AD preventives and 
therapeutics. 
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Figure 1. The mevalonate pathway consisting of steps catalyzed by enzymes including 3-
hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase and FPP and GGPP synthases 
provides farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) for the 
prenylation of proteins regulating neuro functions. FPP also leads to the biosynthesis of sterols 
that elicit feedback inhibition of HMG CoA reductase expression via its transcriptional factor, 
sterol regulatory element binding protein-2 (SREBP-2). Statins and isoprenoids including 
tocotrienols suppress HMG CoA reductase; the former via competitive inhibition and the latter, 
transcriptional downregulation and acceleration of protein degradation. Statins and tocotrienols 
may have preventive and therapeutic values for Alzheimer’s disease through depletion of FPP 
and GGPP. Farnesyl- and geranylgeranyl- transferase inhibitors (FTIs & GGTIs) and 
bisphosphonates may also be neuroprotective by inhibiting prenyl transferases and FPP synthase, 
respectively. Furthermore, tocotrienols may suppress NFκB-mediated neuroinflammation as a 
consequent to FPP and GGPP ablation. The dotted arrow indicates a postulated connection. 
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Figure 2. The structures of tocopherols and tocotrienols. Tocopherols and tocotrienols share a 
common chromanol ring where the number and position of the methyl group determine the 
vitamin E isomers (α, β, γ and δ) within each category, but differ in their side chains. The 
unsaturated farnesyl moiety of tocotrienol is associated with biological activities of tocotrienols 
distinct from those of tocopherols. 
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